REVIEWS: CURRENT TOPICS

Benefits of polyphenols on gut microbiota and implications in human health

Fernando Cardona[a,b,*], Cristina Andrés-Lacueva[c,d], Sara Tulipani[a], Francisco J. Tinahones[b,e,*],
María Isabel Queipo-Ortuño[a,b]

[a]Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (FIMABIS), Málaga, Spain
[b]CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain
[c]Department of Nutrition and Food Science, XaRTA, INSA, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
[d]INGENIO-CONSOLIDER Program, Fun-c-food CSD2007-06, Barcelona, Spain
[e]Servicio Endocrinología y Nutrición del Hospital Virgen de la Victoria, Málaga, Spain

Abstract

The biological properties of dietary polyphenols are greatly dependent on their bioavailability that, in turn, is largely influenced by their degree of polymerization. The gut microbiota play a key role in modulating the production, bioavailability and, thus, the biological activities of phenolic metabolites, particularly after the intake of food containing high-molecular-weight polyphenols. In addition, evidence is emerging on the activity of dietary polyphenols on the modulation of the colonic microbial population composition or activity. However, although the great range of health-promoting activities of dietary polyphenols has been widely investigated, their effect on the modulation of the gut ecology and the two-way relationship "polyphenols ↔ microbiota" are still poorly understood.

Only a few studies have examined the impact of dietary polyphenols on the human gut microbiota, and most were focused on single polyphenol molecules and selected bacterial populations. This review focuses on the reciprocal interactions between the gut microbiota and polyphenols, the mechanisms of action and the consequences of these interactions on human health.
© 2013 Elsevier Inc. All rights reserved.

Keywords: Dietary polyphenols; Gut microbiota; Polyphenol bioavailability; Human health; Cancer; Immunity

1. Introduction

Dietary polyphenols are natural compounds occurring in plants, including foods such as fruits, vegetables, cereals, tea, coffee and wine [1]. Chemically, polyphenols are a large heterogeneous group of compounds characterized by hydroxylated phenyl moieties. Based on their chemical structure and complexity (i.e., the number of phenolic rings and substituting groups), polyphenols are generally classified into flavonoids and nonflavonoids [2]. Flavonoids form a major (over 9000 structurally distinct flavonoids have been identified in nature) heterogeneous subgroup comprising a variety of phenolic compounds with a common diphenylpropane skeleton (C6-C3-C6). In turn, flavonoids are also classified into further subclasses according to their structural differences (flavanones, flavones, dihydroflavonols, flavonols, flavan-3-ols or flavanols, anthocyanidins, isoflavones and proanthocyanidins) [3,4]. In planta, most polyphenols occur in their glycosylated forms, although modifications such as esterification or polymerization are also commonly found. Once ingested, polyphenols are recognized by the human body as xenobiotics, and their bioavailability is therefore relatively low in comparison to micro and macronutrients. Furthermore, depending on their degree of structural complexity and polymerization, these compounds may be readily absorbed in the small intestine (i.e., low-molecular-weight polyphenols such as monomeric and dimeric structures) [5] or reach the colon almost unchanged (oligomeric and polymeric polyphenols such as condensed or hydrolysable tannins, reaching molecular weight values close to 40,000 Da) [6–10]. It has been estimated that only 5–10% of the total polyphenol intake is absorbed in the small intestine. The remaining polyphenols (90–95% of total polyphenol intake) may accumulate in the large intestinal lumen up to the millimolar range where, together with conjugates excreted into the intestinal lumen through the bile, they are subjected to the enzymatic activities of the gut microbial community [11–26]. The colonic microbiota are therefore responsible for the extensive breakdown of the original polyphenolic structures into a series of low-molecular-weight phenolic metabolites that, being absorbable, may actually be

---

* Corresponding authors. F.C. Díaz is to be contacted at: Laboratorio de Investigaciones Biomédicas del Complejo Hospitalario de Málaga (FIMABIS), Campus de Teatinos s/n 29010 Málaga, Spain. Tel.: +34 951032647; fax: +34 951924651. F.J. Tinahones, Servicio Endocrinología y Nutrición, Complejo Hospitalario de Málaga. Campus de Teatinos s/n 29010 Málaga, Spain. Tel.: +34 951032734; fax: +34 951924651.

E-mail addresses: fernandocardonadiaz@gmail.com (F. Cardona), fjtinahones@hotmail.com (F.J. Tinahones).

responsible for the health effects derived from polyphenol-rich food consumption, rather than the original compounds found in foods.

Currently, it is estimated that 500–1000 different microbial species inhabit the gastrointestinal tract, reaching the highest concentrations in the colon (up to 10^{12} cells per gram of faeces). However, only a few bacterial species (*e.g. Escherichia coli*, *Bifidobacterium* sp., *Lactobacillus* sp., *Bacteroides* sp., *Eubacterium* sp.) catalyzing the metabolism of phenolics have been identified so far, together with the catabolic pathways implicated [26]. However, they do not seem to be ubiquitous but reflect the interpersonal differences in the gut microbial community.

Consequently, apart from the interindividual variation in daily intake of polyphenols, interindividual differences in the composition of the gut microbiota may lead to differences in bioavailability and bioefficacy of polyphenols and their metabolites [27,28]. The scenario appears even more complex when considering the two-way relationship "polyphenols ↔ microbiota". Recent studies have in fact suggested that both the phenolic substrates supplied to the gut bacteria through different patterns of dietary intake and the aromatic metabolites produced may in turn modulate and cause fluctuations in the composition of the microflora populations through selective prebiotic effects and antimicrobial activities against gut pathogenic bacteria [29–38]. The formation of bioactive polyphenol-derived metabolites and the modulation of colonic microbiota may both contribute to host health benefits, although the mechanisms have not been delineated. The health properties attributed to beneficial bacteria for human hosts include protection against gastrointestinal disorders and pathogens, nutrient processing, reduction of serum cholesterol, reinforcement of intestinal epithelial cell-tight junctions and increased mucus secretion and modulation of the intestinal immune response through cytokine stimulus [39–41]. Likewise, in the last decade, a growing body of *in vivo* interventional and epidemiological studies has furnished new evidence on the wide range of health promoting activities of dietary polyphenols, already documented by *in vitro* data, including their antiinflammatory, antioxidant, anticarcinogenic, antiadipogenic, antidiabetic and neuroprotective potentials, suggesting an association between the consumption of polyphenol-rich foods and a reduced risk of several chronic diseases [42–48]. However, the effect of dietary polyphenols on the modulation of the gut ecology, including the underlying mechanisms and the actual benefits of such bioactive agents, is still poorly understood.

The aim of this review is to provide an overview of recent reports on the dual nature of polyphenol–microbiota interactions and its relevance to human health.

2. Polyphenols and their biotransformation in the gut

Fig. 1 schematically illustrates the metabolic fate of dietary polyphenols in humans. Briefly, a small percentage of dietary polyphenols (5–10% of the total intake, mainly those with monomeric and dimeric structures) may be directly absorbed in the small intestine, generally after deconjugation reactions such as deglycosylation [7]. After absorption into the small intestine, these less complex polyphenolic compounds may be subjected to extensive Phase I (oxidation, reduction and hydrolysis) and particularly Phase II (conjugation) biotransformations in the enterocytes and then the hepatocytes, resulting in a series of water-soluble conjugate metabolites (methyl, glucuronide and sulfate derivatives) rapidly liberated to the systemic circulation for further distribution to organs and excretion in urine. In the large intestine, colonic bacteria are known to act enzymatically on the polyphenolic backbone of the remaining unabsorbed polyphenols (90–95% of the total polyphenol intake), sequentially producing metabolites with different physiological significance [49]. The metabolism of polyphenols by microbiota

involves the cleavage of glycosidic linkages and the breakdown of the heterocyclic backbone [50]. As an example, the microbial catabolism of proanthocyanidins (oligomers and polymers of flavan-3-ols) has been extensively described in recent years. It results in the sequential production of lactones and aromatic and phenolic acids with different hydroxylation patterns and side-chain lengths, depending on the precursor structures (phenylvalerolactones, phenylvaleric acids, phenylpropionic acids, phenylacetic acids, hippuric and benzoic acids) [11,22]. The metabolism by gut microflora of these polyphenols abundant in wine, tea, chocolate and many fruits may also influence tissue exposure to high-molecular-weight polyphenols, including proanthocyanidins or oxidized polymeric polyphenols, which are poorly absorbed in the proximal part of the gastrointestinal tract [51]. In addition, the microbial transformation of nonflavonoid polymeric molecules called ellagitannins (or hydrolysable tannins) has also been investigated in the last decade [23,24]. After the consumption of ellagitannin-rich food such as strawberries, raspberries, walnuts, oak-aged wines and pomegranates, these tannin structures are subjected to hydrolysis in the intestinal lumen, releasing free ellagic acid. Once in the large intestine, ellagic acid is metabolized by human colonic microflora to produce a series of derivative compounds called urolithins, characterized by a common 6H-dibenzo[b,d]pyran-6-one nucleus and a decreasing number of phenolic hydroxyl groups (urolithin D→C→A→B). All these microbial-derived phenolic metabolites may be absorbed or excreted by faeces. When absorbed, they reach the liver through the portal vein where they may be further subjected to extensive first-pass Phase II metabolism (including glucuronidation, methylation, sulfation or a combination of these) until they finally enter the systemic circulation and are distributed to the organs or eliminated in urine. Microbial glucuronidase and sulphatase activity may also deconjugate the Phase II metabolites extruded *via* the bile throughout the enterohepatic circulation, enabling their reuptake and effective bioavailability. *Clostridium* and *Eubacterium* are the main genera involved in the metabolism of many phenolics such as isoflavones (daidzein), flavonols (quercetin and kaempferol), flavones (naringenin and ixoxanthumol) and flavan-3-ols (catechin and epicatechin) [32]. As *Firmicutes* possess a disproportionately smaller number of glycan-degrading enzymes than *Bacteroidetes* [52], it might be hypothesized that intake of different polyphenols could reshape the gut microbiota differently.

A major fraction of the polyphenols present in the plasma and excreted in urine of rats fed with red wine polyphenols comprises aromatic acid metabolites formed in the gut [53]. Incubating an anthocyanin extract from Cabernet Sauvignon grapes with the contents of the large intestine of pigs for 6 h results in a loss of the parent compound but the generation of three identifiable metabolites [54]. It is possible that these metabolites offer a protective effect against colon cancer, such as decreased carcinogen-induced aberrant crypt formation, colonic cell proliferation and oxidative DNA damage, which have been attributed to anthocyanin consumption [55].

3. Effects of dietary polyphenols on modulation of intestinal ecology

Previous human intervention trials have shown that apart from interindividual variation in the daily intake of polyphenols, interindividual differences in the composition of the human microbiota may lead to differences in bioavailability and bioefficacy of polyphenols and their metabolites [56,57]. In addition, polyphenols may be converted by the colonic microbiota to bioactive compounds that can affect the intestinal ecology and influence host health. There is evidence from *in vitro* animal and human studies that certain doses of selected polyphenols may modify the gut microbial composition, and while certain bacterial groups can be inhibited, others can thrive in the available niche of the ecosystem. Phenolic compounds alter gut

Fig. 1. Routes for dietary polyphenols and their metabolites in humans. Within the host, dietary polyphenols and their microbial metabolites successively undergo intestinal and liver Phase I and II metabolism, biliary secretion, absorption in the systemic circulation, interaction with organs and excretion in the urine.

microbiota and, consequently, alter the *Bacteroides*/*Firmicutes* balance [19,29,58]. For example, Tzounis *et al.*, in an *in vitro* study using a batch-culture model reflective of the distal region of the human large intestine, suggested that flavan-3-ol monomers such as (−)epicatechin and (+)catechin may be capable of influencing the large intestinal bacterial population even in the presence of other nutrients, such as carbohydrates and proteins. These authors found that (+)catechin significantly inhibited growth of *Clostridium histolyticum* and enhanced growth of *E. coli* and members of the *Clostridium coccoides–Eubacterium rectale* group, while growth of *Bifidobacterium* and *Lactobacillus* spp. remained relatively unaffected [59].

Dietary administration of proanthocyanidin-rich extracts also appears to have a similar effect. The faecal bacteria composition of rats whose diet was supplemented for 16 weeks with a dealcoholized, proanthocyanidin-rich red wine extract shifted from a predominance of *Bacteroides*, *Clostridium* and *Propionibacterium* spp. to a predominance of *Bacteroides*, *Lactobacillus* and *Bifidobacterium* spp. [60].

Yamakoshi *et al.* documented that a proanthocyanidin-rich extract from grape seeds given to healthy adults for 2 weeks was able to significantly increase the number of bifidobacteria [61]. Nevertheless, recent studies indicate that monomeric flavan-3-ols and flavan-3-ol-rich sources such as chocolate, green tea and blackcurrant or grape seed extracts may modulate the intestinal microbiota *in vivo*, producing changes in beneficial bacteria such as *Lactobacillus* spp. but inhibiting other groups such *Clostridium* spp. in both *in vivo* and *in vitro* studies [30,59,62,63]. More recently, a cocoa dietary intervention in a rat model showed a significant decrease in the proportion of *Bacteroides*, *Clostridium* and *Staphylococcus* genera in the faeces of cocoa-fed animals [64].

Other rat studies carried out by Smith *et al.* found that when rats were given a tannin-rich diet, the *Bacteroides* group increased significantly while the *Clostridium leptum* cluster decreased significantly [65]. Dolara *et al.* reported that, when rats were treated with red-wine polyphenols, they had significantly lower levels of *Clostridium* spp. and higher levels of *Bacteroides*, *Bifidobacterium* and *Lactobacillus* spp. [60]. Similarly, the resveratrol commonly found in grape promoted faecal cell counts of *Bifidobacterium* spp. and *Lactobacillus* in a rat model [66].

A human intervention study indicated that consumption of red wine polyphenols significantly increased the number of *Enterococcus*, *Prevotella*, *Bacteroides*, *Bifidobacterium*, *Bacteroides uniformis*, *Eggerthella lenta*, and *Blautia coccoides-E. rectale* group while the quantity of *Lactobacillus* spp. was unaltered [31]. On the other hand, when bacteria were cultured with various tea phenolics, the growth of pathogenic bacteria such as *Clostridium perfringens*, *Clostridium difficile* and *Bacteroides* spp. was significantly repressed, while commensal anaerobes like *Bifidobacterium* and *Lactobacillus* were affected less [29]. Vendrame *et al.* found a significant increase in the amount of *Bifidobacterium* after the consumption of a wild blueberry drink, suggesting an important role of the polyphenol present in wild blueberries on the intestinal microbiota composition modulation [67].

Cueva *et al.* analyzed the potential of flavan-3-ols from grape seed to influence the growth of intestinal bacterial groups using *in vitro* fermentation models. They found that the flavan-3-ol profile of a particular food source could affect the microbiota composition (promoting the growth of *Lactobacillus*/*Enterococcus* and decreasing the *C. histolyticum* group) and its catabolic activity, inducing changes that could in turn affect the bioavailability and potential bioactivity of these compounds [68].

Finally, important prebiotic effects and selective antimicrobial activities against gut pathogenic bacteria have also been attributed to the polyphenolic fraction contained in the skin covering the kernel of several nuts, mostly composed of nonflavonoid tannin structures (ellagitannins), flavan-3-ols and proanthocyanidins [36–38].

4. Mechanisms of action of polyphenols on bacterial cell membrane

The influence of polyphenols on bacterial growth and metabolism depends on the polyphenol structure, the dosage assayed and the microorganism strain [34]. For instance, Gram-negative bacteria are more resistant to polyphenols than Gram-positive bacteria, possibly due to the differences found in their wall composition [69]. Recent findings suggest a variety of potential mechanisms of action of polyphenols on bacterial cells. For example, polyphenols can bind to bacterial cell membranes in a dose-dependent manner, thus

disturbing membrane function and therefore inhibiting cell growth [70]. Polyphenols, such as catechins, act on different bacterial species (*E. coli*, *Bordetella bronchiseptica*, *Serratia marcescens*, *Klebsiella pneumonie*, *Salmonella choleraesis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Bacillus subtilis*) by generating hydrogen peroxide [71] and by altering the permeability of the microbial membrane [72]. Sirk *et al.* also reported that the mechanism of antimicrobial, anticancer and other beneficial health effects of catechins and theaflavins may be governed by hydrogen bonding of their hydroxyl groups to lipid bilayers of cell membranes. The molecular structure and aggregated condition of the catechins significantly influences their absorption, as well as their ability to form hydrogen bonds with the lipid head groups. The molecular structure of the catechins and theaflavins influences their configuration when binding to the bilayer surface, as well as their ability to form hydrogen bonds with the lipid head groups [73,74].

Another component of green tea, the (−)-epicatechin gallate (ECg), sensitizes methicillin-resistant *S. aureus* to beta-lactam antibiotics, promotes staphylococcal cell aggregation and increases cell-wall thickness. ECg-mediated alterations of the physical nature of the bilayer can elicit structural changes to wall teichoic acid that result in modulation of the cell-surface properties necessary to maintain the beta-lactam-resistant phenotype [75].

Microbes stressed by exposure to polyphenols up-regulate proteins related to defensive mechanisms, which protect cells while simultaneously down-regulating various metabolic and biosynthetic proteins involved, for example, in amino acid and protein synthesis as well as phospholipid, carbon and energy metabolism [76]. Most bacteria are able to regulate phenotypic characteristics, including virulence factors, as a function of cell density under the control of chemical signal molecules. Polyphenolic compounds can also interfere with bacterial quorum sensing, which is achieved by producing, releasing and detecting small signal molecules identified as auto-inducers (acylated homoserine lactones in Gram-negative bacteria and oligopeptides in Gram-positive bacteria) [77,78]. For example, polyphenols have been reported to interfere with the production of small signal molecules by bacterial cells of *E. coli*, *Pseudomonas putida* and *Burkholderia cepacia* that trigger the exponential growth of a bacterial population [79]. Studies performed with synthesized or isolated Phase II-conjugated metabolites of flavan-3-ols have revealed that they could have an effect beyond their antioxidant properties, by interacting with signalling pathways implicated in important processes involved in the development of diseases [10].

On the other hand, red wine and green tea polyphenols strongly inhibit the VacA toxin, a major virulence factor of *Helicobacter pylori* [80]. The inhibitory mechanisms of dietary polyphenols against *H. pylori* may include suppression of urease activity, affecting bacterial proliferation and damaging bacterial membranes, thus making cells more sensitive to external compounds such as antibiotics and leading to a disruption of proton motive force through the loss of H+− ATPase and membrane-associated functions [81].

Moreover, the B ring of the flavonoids may play a role in intercalation or hydrogen bonding with the stacking of nucleic acid bases, and this may explain the inhibitory action on DNA and RNA synthesis [82]. Plaper *et al.* reported that quercetin binds to the GyrB subunit of *E. coli* DNA gyrase and inhibits the enzyme's ATPase activity [83]. In agreement with these earlier findings, more recently, Gradisar *et al.* determined that the catechins inhibit bacterial DNA gyrase by binding to the ATP (adenosine triphosphate) binding site of the gyrase B subunit [84].

In both *in vivo* and in animal studies, the phenolic substances were suggested to be responsible for the observed anticaries effect of cocoa powder [85], possibly due to their inhibition of the synthesis of water-insoluble glucans [86]. On the other hand, a rich source of flavonoids such as onion extracts has been reported to act on *Streptococcus mutans* and *Streptococcus sobrinus* as well as on *Porphyromonas gingivalis* and *Prevotella intermedia*, which are considered to be the main causal bacteria of adult periodontitis [87].

Another hypothesis leans toward the formation of polyphenol–metal ion complexes, which in turn would lead to iron deficiency in the gut and could, therefore, affect sensitive bacterial populations, mainly aerobic microorganisms [65]. Aerobic microorganisms need iron for several functions, such as reduction of the ribonucleotide precursor of DNA and to form heme groups. In contrast, it has been demonstrated that dietary catechols may promote the growth of enteropathogenic bacteria by providing iron under iron-restrictive conditions and can enable gut bacterial growth [88]. Several mechanisms of action of polyphenols on specific intestinal bacterial functions are still unknown, and further research is needed for a better understanding.

5. Polyphenols, microbiota and cancer

Several studies have linked the microbial metabolism of dietary polyphenols to cancer prevention. These studies have found phylum-level differences among the gut microbiota of patients with and without colorectal cancer. Some phyla are increased, whereas others are decreased, but exactly how these changes affect the cancer process is not clear [89,90]. Studies done *in vitro* and in gnotobiotic rats have shown that plant lignin secoisolariciresinol diglucoside can be converted to enterodiol and enterolactone by a gut microbiota consortia composed of *Clostridium saccharogumia*, *Eggertella lenta*, *Blautia producta* and *Lactonifactor longoviformis* [91,92]. Furthermore, colonization with this lignin-metabolizing microbial community protected germ-free rats from 7,12-dimethylbenz(a)anthracene-induced cancer. Moreover, colonization significantly decreased tumour number, size and cell proliferation but increased tumour cell apoptosis [93].

Some polyphenol dietary components may also influence bacterial metabolizing enzymes and thus influence the overall cancer risk. For example, in a rat model, resveratrol supplementation (8-mg/kg body weight/day, intragastrically) significantly reduced activities of faecal and host colonic mucosal enzymes, such as β-glucoronidase, β-glucosidase, β-galactosidase, mucinase and nitroreductase compared to control animals (21%, 45%, 37%, 41% and 26%, respectively). The reduced bacterial enzyme activity was associated with a significant reduction in colonic tumour incidence in the resveratrol-fed rats compared to control rats, but it is not clear if these changes were a result of modifications of enzymatic activity within a subpopulation of microorganisms or a change in the proportion of specific bacteria [94]. The stilbene resveratrol is important in relation with colon cancer. The antiinflammatory activity of resveratrol includes inhibition of proinflammatory mediators, modification of eicosanoid synthesis and inhibition of enzymes including COX-2, NF-κB, AP-1, TNF-α, IL6 and VEGF (vascular endothelial growth factor) [95]. In cell culture, several phenolic compounds inhibit COX-2 activity, possibly by binding to the enzyme [96].

Ellagic acid has been reported to show a multitude of biological properties including antioxidant and cancer protective activities [97,98]. Interestingly, both urolithins A and B, the most representative microbial metabolites of dietary ellagitannins, have shown oestrogenic activity in a dose-dependent manner, even at high concentrations (40 microM), without antiproliferative or toxic effects towards MCF-7 breast cancer cells [99]. Other authors have analyzed the impact of selected intestinal polyphenol metabolites (with 3,4-dihydroxyphenylacetic acid (ES) and 3-(3,4-dihydroxyphenyl)-propionic acid, metabolites of quercetin and chlorogenic acid/caffeic acid) on modulation of enzymes involved in detoxification and inflammation in LT97 human adenoma cells. They showed an up-regulation of GSTT2 and a down-regulation of COX-2 that could possibly contribute to the chemopreventive potential of polyphenols after degradation in the gut [96]. Recently, Kang *et al.* reported that

coffee and caffeic acid specifically inhibited colon cancer metastasis and neoplastic cell transformation in mice by inhibiting MEK1 and TOPK (T-LAK cell–originated protein kinase) [100]. Several studies using animal and cell culture models have shown that tea-derived catechins, such as epigallocatechin-3-gallate, hold anticancer activity and mediate various cellular events that could be protective against cancer [101,102]. In addition, other nontea flavonoids such as quercetin from apples and vegetables have been found to have anticancer effects, including inhibition of cell proliferation and induction of apoptosis [103]. Whether the concentration of these compounds can be sufficiently achieved in human diets to affect these pathways is not known. Based on these previous studies, multiple mechanisms appear to be involved in the inhibition of carcinogenesis by dietary polyphenols (Fig. 2).

6. Modulation of gut microbiota by polyphenols and the impact on human gut health metabolism and immunity

In the following section, we summarize the effects of polyphenols and metabolites from polyphenol microbial metabolism on specific aspects of health and immunity. After a human intervention study, Tzounis *et al.* reported that flavonols induced an increase in the growth of *Lactobacillus* spp. and *Bifidobacterium* spp. and they may have been partly responsible for the observed reductions in the plasma C-reactive protein (CRP) concentrations, which are a blood marker of inflammation and a hallmark of the acute phase response [30]. Similarly, Fogliano *et al.*, in an *in vitro* model, found that the bacterial fermentation of water-insoluble cocoa fractions was associated with an increase in bifidobacteria and lactobacilli as well as butyrate production. These microbial changes were associated with significant reductions in plasma triacylglycerol and CRP, suggesting the potential benefits associated with dietary inclusion of flavonol-rich foods [104]. Recently, Queipo-Ortuño *et al.* [31] carried out a human intervention study and found that the regular intake of red wine polyphenols generated significant decreases in the plasma levels of blood pressure, triglycerides and high-density lipoprotein choles-

terol, and these significant reductions may be partly due to the polyphenol-induced increase in the growth of *Bacteroides* genera. Moreover, they also reported a significant decrease in uric acid levels after the consumption of red wine polyphenols that can be explained by the significant increase in *Proteobacteria* observed in this stage, which has previously been reported to degrade uric acid [105]. Finally, they noted a significant reduction in the concentration of CRP after red wine treatment. This could be due to the increase seen in the number of *Bifidobacterium*. CRP is a blood marker of inflammation, and its concentration is a specific predictor of cardiovascular event risk in healthy subjects. Its reduction in this study links polyphenol intake to cardiovascular benefits in the host [106,107].

The weight-lowering property of fruits, green tea and vinegar wine in obese people may be partly related to their polyphenol content, which changes the gut microbiota either through the glycan-degrading capability of *Bacteroides*, which is higher than *Firmicutes*, or through the end products of colonic metabolism of polyphenols [33].

Martin *et al.* performed a clinical trial in a population of human subjects classified as having low or high anxiety traits using validated psychological questionnaires. They found that the daily consumption of dark chocolate (which is rich in flavonoids, mainly flavan-3-ols) resulted in a significant modification in the metabolism in healthy and free living human subjects, with potential long-term term health consequences, as per variation of both host and gut microbial metabolism. Human subjects with higher anxiety traits, however, showed a distinct metabolic profile, indicative of a different energy homeostasis (lactate, citrate, succinate, *trans*-aconitate, urea and proline), hormonal metabolism (adrenaline, DOPA [dihidroxifenila-lanina] and 3-methoxy-tyrosine) and gut microbial activity (methyl-amines, *p*-cresol sulfate and hippurate) [108].

Monagas *et al.* observed that dihydroxylated phenolic acids (3,4-dihydroxyphenylpropionic acid, 3-hydroxyphenylpropionic acid and 3,4-dihydroxyphenylacetic acid) derived from microbial metabolism of proanthocyanidins presented marked *in vitro* antiinflammatory properties, reducing the secretion of TNF-α, IL-1b and IL-6 in


Fig. 2. Possible mechanisms proposed for the prevention of cancer by dietary polyphenols.

lipopolysaccharide-stimulated peripheral blood mononuclear cells from healthy subjects. It has been suggested that these microbial metabolites could be among the new generation of therapeutic agents for the management of immunoinflammatory diseases such as atherosclerosis [109], as well as for dampening the inflammatory response to bacterial antigens, which may have implications for chronic inflammatory or autoimmune diseases such as inflammatory bowel disease [110].

Larrosa et al., after screening different microbial catabolites of polyphenols for their antiinflammatory potential in vitro, found that hydrocaffeic, dihydroxyphenylacetic and hydroferulic acid reduced prostaglandin E2 production by at least 50% in CCD-18 colon fibroblast cells stimulated with IL-1β. These results suggest that foods containing significant hydrocaffeic acid precursors (procyanidins, hydroxycinnamic acid derivatives, etc.) such as artichoke, cocoa, apples and strawberries could exert antiinflammatory activity and reduce intestinal inflammation in humans [111].

In addition, it has been shown that microbial metabolites of plant polyphenols may also affect disease risk in the metabolic syndrome. Verzelloni et al. demonstrated that two microbial metabolites of polyphenols, urolithins and pyrogallol derived from ellagitannin are highly antiglycative compared to parent polyphenolic compounds in an in vitro model of protein glycation. Moreover, it is known that protein glycation plays an important pathological role in diabetes and diabetes-associated disorders, including blindness [112].

Tucsek et al. [113] induced an inflammatory response by treating macrophages with bacterial endotoxin and found that end products of polyphenol degradation, such as ferulaldehyde, exerted a beneficial antiinflammatory response by diminishing MAP (mitogen-activated protein) kinase activation, thereby inhibiting NF-κB activation, mitochondrial depolarization and reactive oxygen species production. Similar results were found by Chirumbolo using many purified aglycone flavonoids [114]. It is arguable that the antimicrobial activity of polyphenols might be principally due to their well-recognized antiinflammatory potential.

Very recently, Beloborodova et al. [115] analyzed the role of phenolic acids of microbial origin as biomarkers in the progress of sepsis. They found that p-hydroxyphenylacetic acid showed the capacity to inhibit ROS (reactive oxygen species) production in neutrophils. By affecting neutrophils, they retard the immune response, whereas, while acting on mitochondria, they prevent or reduce the development of multiple organ failure. Thus, during the development of bacteremias and purulent foci of infection associated with P. aeruginosa and Acinetobacter baumanii, their metabolite p-hydroxyphenylacetic acid can directly enter the systemic blood flow and inhibit the phagocytic activity of neutrophils.

Finally, all these results support the hypothesis that not only the food polyphenols but also their microbial metabolites must be taken into account when assessing the impact of polyphenols on host health.

7. Conclusion

The bioavailability and effects of polyphenols greatly depend on their transformation by components of the gut microbiota. Different studies have been carried out to understand the gut microbiota transformation of particular polyphenol types and identify the microorganisms responsible. The modulation of the gut microbial population by phenolics was also reviewed in order to understand the two-way phenolic–microbiota interaction. It is clear that dietary polyphenols and their metabolites contribute to the maintenance of gut health by the modulation of the gut microbial balance through the stimulation of the growth of beneficial bacteria and the inhibition of pathogen bacteria, exerting prebiotic-like effects. However, data on the impact of polyphenols on the gut microbiota and their

mechanisms of action in humans are scarce. In addition, a better understanding of the dietary phenolic and gut microbiota relationship by the combination of metagenomic and metabolomic studies provides more insight into the health effects of polyphenols.

References

[1] Puupponen-Pimiä R, Aura AM, Oksman-Caldentey KM, Myllärinen P, Saarela M, Mattila-Sandholm T, et al. Development of functional ingredients for gut health. Trends Food Sci Tech 2002;13:3–11.
[2] Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, et al. Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. Database 2010, http://dx.doi.org/10.1093/database/bap024.
[3] Bingham M. In: Ouwehand AC, Vaughan EE, editors. Gastrointestinal microbiology. New York: Taylor & Francis Group; 2006. p. 155–68.
[4] Andrés-Lacueva CA, Medina-Remon A, Llorach R, Urpi-Sarda M, Khan N, Chiva-Blanch G, et al. Phenolic compounds: chemistry and occurrence in fruits and vegetables. In: de la Rosa LA, Álvarez-Parrilla E, González-Aguilar GA, editors. Fruit and Vegetable Phytochemicals: Chemistry, Nutritional Value and Stability. Ames, IA: Blackwel Publishing; 2009. p. 53–88.
[5] Appeldoorn MM, Vincken JP, Gruppen H, Hollman PC. Procyanidin dimers A1, A2, and B2 are absorbed without conjugation or methylation from the small intestine of rats. J Nutr 2009;139(8):1469–73.
[6] Bosscher D, Breynaert A, Pieters L, Hermans N. Food-based strategies to modulate the composition of the intestinal microbiota and their associated health effects. J Physiol Pharmacol 2009;60(6):5–11.
[7] Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81(1):230S–42S.
[8] Rasmussen SE, Frederiksen H, Struntze KK, Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res 2005;49(2):159–74.
[9] Walle T. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36(7):829–37.
[10] Monagas M, Urpi-Sarda M, Sánchez-Patán F, Llorach R, Garrido I, Gómez-Cordovés C, et al. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct 2010;1(3):233–53.
[11] Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727–47.
[12] D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 2007;43:348–61.
[13] Jacobs DM, Gaudier E, van Duynhoven J, Vaughan EE. Non-digestible food ingredients, colonic microbiota and the impact on gut health and immunity: a role for metabolomics. Curr Drug Metab 2009;10(1):41–54.
[14] Kroon AP, Clifford NM, Crozier A, et al. How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr 2004;80:15–21.
[15] Manach C, Donovan LJ. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Rad Res 2004;38:771–85.
[16] Serrano J, Puupponen-Pimiä R, Dauer A, Aura AM, Saura-Calixto F. Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol Nutr Food Res 2009;53:S310–29.
[17] Appeldoorn MM, Vincken JP, Aura AM, Hollman PC, Gruppen H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl) acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. J Agric Food Chem 2009;57(3):1084–92.
[18] Urpi-Sarda M, Garrido I, Monagas M, Gómez-Cordovés C, Medina-Remón A, Andres-Lacueva C, et al. Profile of plasma and urine metabolites after the intake of almond [Prunus dulcis (Mill.) D.A. Webb] polyphenols in humans. J Agri. Food Chem 2009;57(21):10134–42.
[19] Stoupi S, Williamson G, Drynan JW, Barron D, Clifford MN. A comparison of the in vitro biotransformation of (−)-epicatechin and procyanidin B2 by human faecal microbiota. Mol Nutr Food Res 2010;54(6):747–59.
[20] Déprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, et al. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J Nutr 2000;130(11):2733–8.
[21] Boto-Ordóñez M, Urpi-Sarda M, María Monagas M, Tulipani S, Llorach R, Rabassa-Bonet M, et al. Phenolic acids from microbial metabolism of dietary flavan-3-ols. In: Munné-Bosch Sergi, editor. Phenolic Acids: Composition, Applications and Health Benefits. Nova Science Publishers (EEUU) Inc.; 2011. p. 147–72.

[22] Saura-Calixto F, Serrano J, Goñi I. Intake and bioaccessibility of total polyphenols in a whole diet. Food Chem 2007;101:492–501.

[23] Espín JC, González-Barrio R, Cerdá B, López-Bote C, Rey AI, Tomás-Barberán FA. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 2007;55(25): 10476–85.

[24] Larrosa M, García-Conesa MT, Espín JC, Tomás-Barberán FA. Ellagitannins, ellagic acid and vascular health. Mol Aspects Med 2010;31(6):513–39.

[25] Rothwell JA, Urpi-Sarda M, Boto-Ordoñez M, Knox C, Llorach R, Eisner R, et al. Phenol-Explorer 2.0: a major update of the Phenol-Explorer database integrating data on polyphenol metabolism and pharmacokinetics in humans and experimental animals. Database 2012, http://dx.doi.org/10.1093/database/bas031.

[26] Kutschera M, Engst W, Blaut M, Braune A. Isolation of catechin-converting human intestinal bacteria. J Appl Microbiol 2011;111:165–75.

[27] Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 2005;53(2):227–35.

[28] Gross G, Jacobs DM, Peters S, Possemiers S, van Duynhoven J, Vaughan EE, et al. In vitro bioconversion of polyphenols from black tea and red wine/grape juice by human intestinal microbiota displays strong interindividual variability. J Agric Food Chem 2010;58(18):10236–46.

[29] Lee HC, Jenner AM, Low CS, Lee YK. Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. Res Microbiol 2006;157(9): 876–84.

[30] Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JP. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr 2011;93(1):62–72.

[31] Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, et al. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012;95(6):1323–34.

[32] Selma MV, Espin JC, Tomas-Barberan FA. Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem 2009;57:6485–501.

[33] Rastmanesh R. High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction. Chem Biol Interact 2011;189(1–2):1–8.

[34] Hervert-Hernandez D, Goñi I. Dietary polyphenols and human gut microbiota: a review. Food Rev Int 2011;27:154–69.

[35] Laparra JM, Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 2010;61(3):219–25.

[36] Mandalari G, Bisignano C, D'Arrigo M, Ginestra G, Arena A, Tomaino A, et al. Antimicrobial potential of polyphenols extracted from almond skins. Lett Appl Microbiol 2010;51(1):83–9.

[37] Mandalari G, Faulks RM, Bisignano C, Waldron KW, Narbad A, Wickham MS. In vitro evaluation of the prebiotic properties of almond skins (Amygdalus communis L.). FEMS Microbiol Lett 2010;304(2):116–22.

[38] Oliveira I, Sousa A, Morais JS, Ferreira IC, Bento A, Estevinho L, et al. Chemical composition, and antioxidant and antimicrobial activities of three hazelnut (Corylus avellana L.) cultivars. Food Chem Toxicol 2008;46(5):1801–7.

[39] Duggan C, Gannon J, Walker WA. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 2002;75:789–808.

[40] Gotteland M, Andrews M, Toledo M, Muñoz L, Caceres P, Anziani A, et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. Nutr 2008;24(5):421–6.

[41] Vitali B, Ndagijimana M, Cruciani F, Carnevali P, Candela M, Guerzoni ME, et al. Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol 2010;10:4.

[42] Jennings A, Welch AA, Fairweather-Tait SJ, Kay C, Minihane AM, Chowienczyk P, et al. Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. Am J Clin Nutr 2012;96(4):781–8.

[43] Cassidy A, O'Reilly ÉJ, Kay C, Sampson L, Franz M, Forman JP, et al. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr 2011;93(2):338–47.

[44] Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012;95(3):740–51.

[45] Chiva-Blanch G, Urpi-Sarda M, Ros E, Valderas-Martinez P, Casas R, Arranz S, et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin Nutr 2012, http://dx.doi.org/10.1016/j.clnu.2012.08.022 [Epub ahead of print].

[46] Chiva-Blanch G, Urpi-Sarda M, Ros E, Arranz S, Valderas-Martinez P, Casas R, et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication. Circ Res 2012;111(8):1065–8.

[47] Zamora-Ros R, Agudo A, Luján-Barroso L, Romieu I, Ferrari P, Knaze V, et al. Dietary flavonoid and lignan intake and gastric adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 2012;96(6):1398–408.

[48] Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H, et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 2010;11(4):1365–402.

[49] Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 2003;41:631–6.

[50] Aura AM, Martin-Lopez P, O'Leary KA, Williamson G, Oksman-Caldentey KM, Poutanen K, et al. In vitro metabolism of anthocyanins by human gut microflora. Eur J Nutr 2005;44:133–42.

[51] Santos-Buelga C, Scalbert A. Proanthocyanidins and tannin-like compounds: nature, occurrence, dietary intake and effects on nutrition and health. J Sci Food Agric 2000;80:1094–117.

[52] Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 2009;106:5859–64.

[53] Gonthier MP, Cheynier V, Donovan JL, Manach C, Morand C, Mila I, et al. Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols. J Nutr 2003;133(2):461–7.

[54] Forester SC, Waterhouse A. Identification of Cabernet Sauvignon anthocyanin gut microflora metabolites. J Agric Food Chem 2008;56(19):9299–92304.

[55] Lala G, Malik M, Zhao C, He J, Kwon Y, Giusti MM, et al. Anothocanin-rich extracts inhibits multiple biomarkers of colon cancer in rats. Nutr 2006;54:84–93.

[56] Bolca S, Urpi-Sarda M, Blondeel P, Roche N, Vanhaecke L, Possemiers S, et al. Disposition of soy isoflavones in normal human breast tissue. Am J Clin Nutr 2010;91(4):976–84.

[57] van Dorsten FA, Grün CH, van Velzen EJ, Jacobs DM, Draijer R, van Duynhoven JP. The metabolic fate of red wine and grape juice polyphenols in humans assessed by metabolomics. Mol Nutr Food Res 2010;54(7):897–908.

[58] Hervert-Hernandez D, Pintado C, Rotger R, Goni I. Stimulatory role of grape pomace polyphenols on Lactobacillus acidophilus growth. Int J Food Microbiol 2009;136:119–22.

[59] Tzounis X, Vulevic J, Kuhnle GG, George T, Leonczak J, Gibson GR, et al. Flavanol monomer-induced changes to the human faecal microflora. Br J Nutr 2008;99:782–92.

[60] Dolara P, Luceri C, De Filippo C, Femia AP, Giovannelli L, Caderni G, et al. Red wine polyphenols influence carcinogenesis, intestinal microflora, oxidative damage and gene expression profiles of colonic mucosa in F344 rats. Mutat Res 2005;591:237–46.

[61] Yamakoshi J, Tokutake S, Kikuchi M. Effect of proanthocyanidin- rich extract from grape seeds on human fecal flora andfecal odor. Microb Ecol Health Dis 2001;13:25–31.

[62] Molan AL, Liu Z, Kruger M. The ability of blackcurrant extracts to positively modulate key markers of gastrointestinal function in rats. World J Microbiol Biotechnol 2011;26:1735–43.

[63] Viveros A, Chamorro S, Pizarro M, Arija I, Centeno C, Brenes A. Effects of dietary polyphenol-rich grape products on intestinal microflora and gut morphology in broiler chicks. Poult Sci 2011;90:566–78.

[64] Massot-Cladera M, Pérez-Berezo T, Franch A, Castell M, Pérez-Cano FJ. Cocoa modulatory effect on rat faecal microbiota and colonic crosstalk. Arch Biochem Biophys 2012;527(2):105–12.

[65] Smith AH, Zoetendal E, Mackie RI. Bacterial mechanisms to overcome inhibitory effects of dietary tannins. Microb Ecol 2005;50:197–205.

[66] Larrosa M, Yáñez-Gascón MJ, Selma MA, González-Sarrías A, Toti S, Cerón JJ, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 2009;57: 2211–20.

[67] Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M. Six-week consumption of a wild blueberry powder drink increases bifidobacteria in the human gut. J Agric Food Chem 2011;59(24):12815–20.

[68] Cueva C, Sánchez-Patán F, Monagas M, Walton GE, Gibson GR, Martín-Álvarez PJ, et al. In vitro fermentation of grape seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups and phenolic metabolites. FEMS Microbiol Ecol 2012, http://dx.doi.org/10.1111/1574-6941.12037.

[69] Puupponen-Pimiä R, Nohynek L, Hartman-Schmidlin S, Kähkönen M, Heinonen M, Mata-Riihinen K, et al. Berry phenolics selectively inhibit the growth of intestinal pathogens. J Appl Microbiol 2005;98:991–1000.

[70] Kemperman RA, Bolca S, Roger LC, Vaughan EE. Novel approaches for analysing gut microbes and dietary polyphenols: challenges and opportunities. Microbiology 2010;156(11):3224–31.

[71] Haslam E, Lilley TH, Warminski E, Liao H, Cai Y, Martin R, et al. Polyphenol complexation. A study in molecular recognition. ACS Symp Ser 1992;506:8–50.

[72] Hattori M, Kusumoto IT, Namba T, Ishigami T, Hara Y. Effect of tea polyphenols on glucan synthesis by glucosyltransferase from Streptococcus mutans. Chem Pharm Bull 1990;38:717–20.

[73] Sirk TW, Friedman M, Brown EF. Molecular binding of black tea theaflavins to biological membranes: relationship to bioactivities. J Agric Food Chem 2011;59(8):3780–7787.

[74] Sirk TW, Brown EF, Friedman M, Sum AK. Molecular binding of catechins to biomembranes: relationship to biological activity. J Agric Food Chem 2009;57(15):6720–8.

[75] Stapleton PD, Shah S, Ehlert K, Hara Y, Taylor PW. The beta-lactam-resistance modifier (−)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology 2007;153(7):2093–103.

[76] Hu L, Wang H, Pei J, Liu Y. Research progress of antitumor effects of resveratrol and its mechanism. Shandong Yiyao 2010;50:111–2.

[77] González JE, Keshavan ND. Messing with bacterial quorum sensing. Microbiol Mol Biol Rev 2006;70(4):859–75.

[78] Williams P. Quorum sensing, communication and cross-kingdom signalling in the bacterialwWorld. Microbiology 2007;153:3923–38.

[79] Hubert B, Eberl L, Feucht W, Polster J. Influence of polyphenols on bacterial biofilm formation and quorum-sensing. Z Naturforsch 2003;58:879–84.

[80] Tombola F, Campello S, De Luca L, Ruggiero P, Del Giudice G, Papini E, et al. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen *Helicobacter pylori*. FEBS Lett 2003;543:184–9.

[81] Lin YT, Vattem DA, Labbe RG, Shetty K. Inhibition of *Helicobacter pylori* by phenolic phytochemical enriched alcoholic beverages. Process Biochem 2005;40(6):2059–65.

[82] Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005;26(5):343–56.

[83] Plaper A, Golob M, Hafner I, Oblak M, Solmajer T, Jerala R. Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun 2003;306(2):530–6.

[84] Gradišar H, Pristovsek P, Plaper A, Jerala R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem 2007;50(2): 264–71.

[85] Park KM, You JS, Lee HY, Baek NI, Hwang JK. Kuwanon G: an antibacterial agent from the root bark of Morus alba against oral pathogens. J Ethnopharmacol 2003;84:181–5.

[86] Percival RS, Devine DA, Duggal MS, Chartron S, Marsh PD. The effect of cocoa polyphenols on the growth, metabolism, and biofilm formation by *Streptococcus mutans* and *Streptococcus sanguinis*. Eur J Oral Sci 2006;114:343–8.

[87] Prabu GR, Gnanamani A, Sadulla S. Guaijaverin—a plant flavonoid as potential antiplaque agent against Streptococcus mutans. J Appl Microbiol 2006;101: 487–95.

[88] Freestone PEF, Walton NJ, Haigh R, Lyte M. Influence of dietary catechols on the growth of enteropathogenic bacteria. Int J Food Microbiol 2007;119:159–69.

[89] Duttona RJ, Turnbaugh PJ. Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr Metab Care 2012;15:448–54.

[90] Macdonald RS, Wagner K. Influence of dietary phytochemicals and microbiota on colon cancer. J Agric Food Chem 2012;60:6728–35.

[91] Woting A, Clavel T, Loh G, Blaut M. Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiol Ecol 2010;72:507–14.

[92] Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007;137:751S–5S.

[93] Mabrok HB, Klopfleisch R, Ghanem KZ, Clavel T, Blaut M, Loh G. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 2012;33:203–8.

[94] Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 2006;96(1):145–53.

[95] Namasivayam N. Chemoprevention in experimental animals. Ann N Y Acad Sci 2011;1215:60–71.

[96] Miene C, Weise A, Glei M. Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human colon cells (LT97). Nutr Cancer 2011;63(4):653–62.

[97] Losso JN, Bansode RR, Trappey 2nd A, Bawadi HA, Truax R. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 2004;15(11):672–8.

[98] Tulipani S, Urpi-Sarda M, García-Villalba R, Rabassa M, López-Uriarte P, Bullo M, et al. Urolithins are the main urinary microbial-derived phenolic metabolites discriminating a moderate consumption of nuts in free-living subjects with diagnosed metabolic syndrome. J Agric Food Chem 2012;60(36):8930–40.

[99] Larrosa M, González-Sarrías A, García-Conesa MT, Tomás-Barberán FA, Espín JC. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 2006;54(5):1611–20.

[100] Kang NJ, Lee KW, Kim BH, Bode AM, Lee HJ, Heo YS, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis 2011;32:921–8.

[101] Butt MS, Sultan MT. Green tea: nature's defense against malignancies. Crit Rev Food Sci Nutr 2009;49:463–73.

[102] Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011;82(12):1807–21.

[103] Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evidence-Based Complement Alternat Med 2011, http://dx.doi.org/10.1093/ecam/meq053.

[104] Fogliano V, Corollaro ML, Vitaglione P, Napolitano A, Ferracane R, Travaglia F, et al. In vitro bioaccessibility and gut biotransformation of polyphenols present in the water-insoluble cocoa fraction. Mol Nutr Food Res 2011;55(1):44–55.

[105] Self WT. Regulation of purine hydroxylase and xanthine dehydrogenase from *Clostridium purinolyticum* in response to purines, selenium, and molybdenum. J Bacteriol 2002;184(7):2039–44.

[106] Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007;50(12): 1115–22.

[107] Ridker PM, Cook NR. Biomarkers for prediction of cardiovascular events. N Engl J Med 2007;356(14):1472–3.

[108] Martin FP, Rezzi S, Peré-Trepat E, Kamlage B, Collino S, Leibold E, et al. Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects. J Proteome Res 2009;8(12):5568–79.

[109] Monagas M, Khan N, Andreś-Lacueva C, Urpí-Sarda M, Vazquez-Agell M, Lamuela-Raventós RM, et al. Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells. Br J Nutr 2009;102:201–6.

[110] Tuohy KM, Conterno L, Gasperotti M, Viola R. Up-regulating the human intestinal microbiome using whole plant foods, polyphenols, and/or fiber. J Agric Food Chem 2012;60(36):8776–82.

[111] Larrosa M, Luceri C, Vivoli E, Pagliuca C, Lodovici M, Moneti G, et al. Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models. Mol Nutr Food Res 2009;53:1044–54.

[112] Verzelloni E, Pellacani C, Tagliazucchi D, Tagliaferri S, Calani L, Costa LG, et al. Antiglycative and neuroprotective activity of colon derived polyphenol catab-olites. Mol Nutr Food Res 2011;55(1):S35–43.

[113] Tucsek Z, Radnai B, Racz B, Debreceni B, Priber JK, Dolowschiak T, et al. Suppressing LPS-induced early signal transduction in macrophages by a polyphenol degradation product: a critical role of MKP-1. J Leukoc Biol 2011;89:105–11.

[114] Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets 2010;9:263–85.

[115] Beloborodova N, Bairamov I, Olenin A, Shubina V, Teplova V, Fedotcheva N. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci 2012;19:89.